Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Sepsis 1Infections 1Hematologic Neoplasms 1

Interventions

ceftolozane, tazobactam drug combination 2Meropenem 2Itraconazole 2rasburicase 1pegylated granulocyte colony-stimulating factor 1pegaspargase 1fludarabine phosphate 1fludarabine 1eltrombopag 1drotrecogin alfa activated 1dexamethasone 21-phosphate 1Voriconazole 1Vancomycin 1Uric Acid 1Urate Oxidase 1Tropisetron 1Teicoplanin 1Solutions 1Ribavirin 1Pegloticase 1Oxidoreductases 1Ofloxacin 1Micafungin 1Metronidazole 1Imatinib Mesylate 1Hydromorphone 1Human Papillomavirus Recombinant Vaccine nonavalent 1Dexamethasone 1Dasatinib 1Ciprofloxacin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Hematologic Neoplasms × drotrecogin alfa activated × Clear all
NCT00067730 2007-12-07

A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation

Eli Lilly and Company

Phase 4 Completed
7 enrolled
Other hematologic neoplasm

Infections, Sepsis, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡